Proteus Digital Health Makes Appointments
This article was originally published in Scrip
Proteus Digital Health, a company creating a new category of therapy known as digital medicines, has appointed Molly O'Neill chief commercial officer (CMO), Shumeet Banerji to its board of directors and Jonathan Symonds as chair. O'Neill brings 30 years of experience to Proteus and is joining from Tenet Health, where she was vice president of business development. Symonds is currently chair of HSBC Bank Plc., chair of the supervisory board of Innocoll AG and non-executive director of Genomics England. Previously he was chief financial officer (CFO) of Novartis, partner and managing director of Goldman Sachs and CFO of AstraZeneca Plc. Banerji is founder and partner of Condorcet, an investment and advisory firm, and he retired from Booz & Company Inc. having served as its founding CEO. He previously held leadership roles at Allen & Hamilton in India, UK and globally. Currently he serves on the board of HP, Inc. and Innocoll, AG.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.